Bioson Pharmaceutical Reports 71.3 Billion KRW in Sales Last Year... Focus on Pharmaceutical Business Leads to Profit Turnaround

Vivozon Pharmaceutical announced on the 21st that its consolidated sales last year reached 71.3 billion KRW, a 20.7% increase compared to the same period the previous year. Operating profit turned positive to 2.7 billion KRW during the same period.

The company explained that the results of focusing solely on the pharmaceutical business after divesting non-profitable businesses such as the optical business and healthcare division are becoming visible.

By business segment, the ethical drugs (ETC) division accounted for more than half of total sales last year, maintaining solid performance. Respiratory drugs such as Celtaplu saw a sharp increase in sales due to the flu epidemic, and chronic disease treatments including Atorvastatin tablets (hyperlipidemia), JBCA tablets (hypertension), Choline salicylate tablets (cognitive enhancer), and Daparozin tablets (diabetes treatment) also drove strong results.

The contract manufacturing organization (CMO) business achieved a 27% growth in scale compared to the previous year, entering a full-fledged growth phase. This was largely due to increased production facilities for liquid and syrup products, which are the main production items, and the acquisition of new contract clients. Additionally, the over-the-counter (OTC) division also saw a 186% increase in sales compared to the previous year after signing an exclusive supply contract for the fatigue recovery product ‘Lalaola Liquid’ with Yuhan Corporation last year.

A company official stated, “The improvement in performance through structural reform is expected to continue this year. In particular, with the sales approval of the non-narcotic analgesic Onapraju (Opiranzerin) this year, we expect it to be a year of significant performance quantum leap.”

Meanwhile, Vivozon Pharmaceutical applied for product approval for the non-narcotic analgesic Onapraju (Opiranzerin) to the Ministry of Food and Drug Safety in November last year.